Mono- or di-substituted imidazole derivatives for inhibition of acetylcholine and butyrylcholine esterases.


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
05 2019
Historique:
received: 26 10 2018
revised: 18 01 2019
accepted: 19 01 2019
pubmed: 4 2 2019
medline: 1 4 2020
entrez: 4 2 2019
Statut: ppublish

Résumé

Mono- or di-substituted imidazole derivatives were synthesized using a one-pot, two-step strategy. All imidazole derivatives were tested for AChE and BChE inhibition and showed nanomolar activity similar to that of the test compound donepezil and higher than that of tacrine. Structure activity relationship studies, docking studies to on X-ray crystal structure of AChE with PDB code 1B41, and adsorption, distribution, metabolism, and excretion (ADME) predictions were performed. The synthesized core skeleton was bound to important regions of the active site of AChE such as the peripheral anionic site (PAS), oxyanion hole (OH), and anionic subsite (AS). Selectivity of the reported test compounds was calculated and enzyme kinetic studies revealed that they behave as competitive inhibitors, while two of the test compounds showed noncompetitive inhibitory behavior. ADME predictions revealed that the synthesized molecules might pass through the blood brain barrier and intestinal epithelial barrier and circulate freely in the blood stream without binding to human serum albumin. While the toxicity of one compound on the WS1 (skin fibroblast) cell line was 1790 µM, its toxicity on the SH-SY5Y (neuroblastoma) cell line was 950 µM.

Identifiants

pubmed: 30711701
pii: S0045-2068(18)31309-9
doi: 10.1016/j.bioorg.2019.01.044
pii:
doi:

Substances chimiques

Cholinesterase Inhibitors 0
Imidazoles 0
imidazole 7GBN705NH1
Acetylcholinesterase EC 3.1.1.7
Butyrylcholinesterase EC 3.1.1.8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-196

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Burak Kuzu (B)

Pharmaceutical Chemistry Section, Van Yuzuncu Yil University, 65080 Van, Turkey; SAFF Chemical Reagent R&D Lab. YYU-TEKNOKENT, 65080 Van, Turkey.

Meltem Tan (M)

Pharmaceutical Chemistry Section, Van Yuzuncu Yil University, 65080 Van, Turkey; SAFF Chemical Reagent R&D Lab. YYU-TEKNOKENT, 65080 Van, Turkey.

Parham Taslimi (P)

Department of Chemistry, Atatürk University, 25240 Erzurum, Turkey.

İlhami Gülçin (İ)

Department of Chemistry, Atatürk University, 25240 Erzurum, Turkey.

Mehmet Taşpınar (M)

Department of Medicinal Biology, Van Yuzuncu Yil University, 65080 Van, Turkey.

Nurettin Menges (N)

Pharmaceutical Chemistry Section, Van Yuzuncu Yil University, 65080 Van, Turkey; SAFF Chemical Reagent R&D Lab. YYU-TEKNOKENT, 65080 Van, Turkey. Electronic address: nurettinmenges@yyu.edu.tr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH